截至月份: 2025年12月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 訊飛醫療科技股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 非上市股份 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 43,581,121 RMB | | | 1 RMB | | 43,581,121 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 43,581,121 RMB | | | 1 RMB | | 43,581,121 | | 2. 股份分類 | 普通股 | 股份類別 | H ...

Core Viewpoint - The AI medical market has significant potential, and iFlytek Medical Technology (02506) possesses a self-developed foundational large model, continuously enhancing its performance ceiling. The company is the most prominent player in the AI medical sector, benefiting from policy incentives and national projects, warranting ongoing attention [1]. Group 1: Shareholder Actions - Major shareholders, including the parent company iFlytek Co., Ltd. and key investors, voluntarily extended the lock-up period for their shares by one year until December 29, 2026, committing not to reduce their holdings during this period. As of the announcement date, these shareholders collectively held 52,758,395 H-shares, accounting for 68.25% of the total H-share capital and 72.86% of the total share capital [2]. - The voluntary extension of the lock-up period reflects the high recognition of the company's future development by key stakeholders, indirectly confirming the AI medical strategy and long-term growth potential. The high shareholding ratio of core shareholders helps stabilize market growth expectations and supports stock prices positively [3]. Group 2: Technological Advancements - In March 2025, the company launched the "iFlytek Spark Medical Model X1," the only medical deep reasoning model fully trained using domestically produced computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0%. By July 2025, the model's capabilities were upgraded, with the general auxiliary diagnosis accuracy improving to 95.0%, health consultation response rate to 91.5%, and major cardiovascular diagnosis accuracy to 91.2%. The model significantly outperformed international counterparts like OpenAI o3 and DeepSeek R1 in key medical tasks [4]. - The deep integration of the self-developed "Spark" model provides the company with a strong technological barrier, ensuring data security and autonomous control, which are critical for government and large public hospitals. This creates a significant entry advantage in the G-end and B-end markets [4]. Group 3: Market Outlook and Financial Projections - The integration of AI in healthcare is a clear direction for policy growth, with the company positioned to benefit as a leading player. Despite traditional medical IT investments facing pressure, the government emphasizes using AI to enhance grassroots diagnosis and optimize resource allocation, as outlined in various policy documents [5]. - Revenue forecasts for the company are projected at 930 million yuan, 1.21 billion yuan, and 1.58 billion yuan for 2025, 2026, and 2027, respectively, with corresponding price-to-sales ratios of 8.5x, 6.5x, and 5x [5].

Core Viewpoint - The AI medical market has significant potential, and iFlytek Medical Technology (02506) possesses a self-developed foundational model, continuously enhancing its performance ceiling. The company is the primary beneficiary of policy dividends and national projects in the AI medical sector, warranting ongoing attention [1]. Group 1: Shareholder Actions - Major shareholders, including the parent company iFlytek (002230) and key investors, voluntarily extended the lock-up period for their shares by one year until December 29, 2026, committing not to reduce their holdings during this period. As of the announcement date, these shareholders collectively held 52,758,395 H-shares, accounting for 68.25% of the total H-share capital and 72.86% of the total share capital [1][2]. Group 2: Technology and Product Development - In March 2025, the company launched the "iFlytek Spark Medical Model X1," the only medical deep reasoning model fully trained using domestically produced computing power. In real-world testing, its general auxiliary diagnosis accuracy reached 94.0%. By July 2025, the model's capabilities were upgraded, with the general auxiliary diagnosis accuracy improving to 95.0%, and other performance metrics also showing significant enhancements [3]. - The company’s deep reliance on its self-developed "Spark" model, based entirely on domestic computing power, provides two core advantages: strong market entry barriers due to data security and autonomy, especially in government and large public hospitals, and a feedback loop for continuous improvement of the model through accumulated data and application experience [3]. Group 3: Market and Policy Environment - The AI+medical sector is a clear direction for policy growth, with the company positioned to benefit significantly from this trend. Amid tightening fiscal and healthcare cost controls, traditional medical IT investments face pressure, while AI is recognized as a means to enhance grassroots diagnosis and optimize resource allocation, supported by various national policies [4]. - Revenue forecasts for the company are projected at 930 million yuan, 1.21 billion yuan, and 1.58 billion yuan for 2025-2027, with corresponding price-to-sales ratios of 8.5x, 6.5x, and 5x [4].

Core Viewpoint - iFlytek Medical Technology (02506) has seen a stock increase of over 4%, currently trading at HKD 78.35 with a transaction volume of HKD 7.8092 million [1] Group 1: Shareholder Commitment - Eight shareholders, including iFlytek and Kexin Venture Capital, have committed not to reduce their holdings of the company's H-shares or unlisted shares until December 29, 2026 [1] - These eight shareholders collectively hold 55.7584 million H-shares, representing 68.25% of the total H-share capital of the company [1] - They also hold a total of 88.0682 million shares, accounting for 72.86% of the company's total share capital [1] Group 2: Strategic Cooperation - iFlytek Medical has signed a strategic cooperation agreement with the Affiliated Hospital of Tianjin University of Traditional Chinese Medicine [1] - This strategic partnership is seen as a significant milestone for iFlytek Medical in expanding its presence in the smart healthcare sector [1] - The collaboration is also viewed as a new opportunity for the Affiliated Hospital to achieve technological upgrades through the use of advanced technology [1]

每经AI快讯，讯飞医疗科技(02506.HK)涨超4%，截至发稿，涨4.19%，报78.35港元，成交额780.92万港 元。 ...

Core Viewpoint - iFlytek Medical Technology (02506) has seen a stock increase of over 4%, currently trading at 78.35 HKD with a transaction volume of 7.8092 million HKD, indicating positive market sentiment towards the company following recent announcements [1] Group 1: Shareholder Commitment - Eight shareholders, including iFlytek (002230) and Kexin Venture Capital, have committed not to reduce their holdings of H-shares or unlisted shares until December 29, 2026, enhancing investor confidence [1] - These eight shareholders collectively hold 55.7584 million H-shares, representing 68.25% of the total H-share capital, and a total of 88.0682 million shares, accounting for 72.86% of the company's total share capital [1] Group 2: Strategic Partnership - iFlytek Medical has signed a strategic cooperation agreement with the Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, marking a significant milestone in the company's expansion in the smart healthcare sector [1] - This partnership is seen as a new opportunity for the hospital to achieve technological upgrades through collaboration with iFlytek Medical [1]

Group 1 - The core viewpoint of the article highlights the significant increase in the stock price of iFlytek Medical Technology, which rose by 4.19% to HKD 78.35, with a trading volume of HKD 7.8092 million [1] - iFlytek Medical announced that eight shareholders, including iFlytek and Kexin Venture Capital, have committed not to reduce their holdings of H-shares or unlisted shares until December 29, 2026. These shareholders collectively hold 55.7584 million H-shares, representing 68.25% of the total H-share capital, and 88.0682 million shares, accounting for 72.86% of the total share capital [1] - The company has signed a strategic cooperation agreement with the Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, marking an important milestone in its expansion in the smart medical field and providing a new opportunity for the hospital to achieve technological upgrades [1]

Group 1 - The stock of iFlytek Medical Technology (02506.HK) rose over 4% in early trading, currently up 4.09% at 75 HKD [2] - The trading volume reached 10.52 million HKD [2]

Core Viewpoint - Xunfei Medical Technology's stock price increased by 6.04% to HKD 76.40, with a trading volume of HKD 13.89 million, indicating positive market sentiment towards the company [1][5]. Group 1: Shareholder Commitment - Eight shareholders, including Keda Xunfei and Kexun Venture Capital, have committed not to reduce their holdings of H-shares or unlisted shares from the end of the original lock-up period until December 29, 2026 [1][5]. - These shareholders collectively hold 55.7584 million H-shares, representing 68.25% of the total H-share capital, and 88.0682 million shares, accounting for 72.86% of the total share capital [1][5]. Group 2: Company Outlook - The company interprets the extension of the lock-up period as a sign of confidence from the shareholders regarding its future prospects [1][5]. - Shareholders will continue to review the company's performance and may consider further extending the lock-up period based on business development [1][5].

Core Viewpoint - iFlytek Medical Technology (02506) experienced a rise of over 4% in early trading, reflecting positive market sentiment following the announcement of a lock-up period extension for major shareholders [1] Group 1: Shareholder Commitment - Eight shareholders, including iFlytek and Kexin Venture Capital, have committed not to reduce their holdings of H-shares or unlisted shares until December 29, 2026 [1] - These shareholders collectively hold 55.7584 million H-shares, representing 68.25% of the total H-share capital, and 88.0682 million shares, accounting for 72.86% of the total share capital [1] - The company interprets the extension of the lock-up period as a sign of confidence in its future prospects from these shareholders [1] Group 2: Future Considerations - The shareholders will continue to review the company's performance and may consider further extending the lock-up period based on the company's business development [1]